{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:04:06Z","timestamp":1793963046338,"version":"4.8.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jaccao.2022.09.007","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T14:27:36Z","timestamp":1673965656000},"page":"85-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pharmacovigilance Analysis of Heart\u00a0Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5960-8801","authenticated-orcid":false,"given":"Sarah","family":"Waliany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Caswell-Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fauzia","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Myall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaccao.2022.09.007_bib1","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.jaccao.2022.09.007_bib2","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/bcr2124","article-title":"Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures","volume":"10","author":"Wirapati","year":"2008","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.jaccao.2022.09.007_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.jaccao.2022.09.007_bib4","first-page":"65","article-title":"Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer","volume":"15","author":"Yano","year":"2006","journal-title":"Oncol Rep"},{"issue":"18_suppl","key":"10.1016\/j.jaccao.2022.09.007_bib5","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/jco.2006.24.18_suppl.4089","article-title":"Correlation between HER2\/neu overexpression\/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): a\u00a0prospective study","volume":"24","author":"Gravalos","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.09.007_bib6","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1038\/sj.onc.1207485","article-title":"Upregulation of IKK\u03b1\/IKK\u03b2 by integrin-linked kinase is required for HER2\/neu-induced NF-\u03baB antiapoptotic pathway","volume":"23","author":"Makino","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.jaccao.2022.09.007_bib7","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1038\/sj.onc.1205438","article-title":"AKT2 is frequently upregulated in HER-2\/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival","volume":"21","author":"Bacus","year":"2002","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.jaccao.2022.09.007_bib8","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","article-title":"Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: Implications for herceptin-induced cardiomyopathy","volume":"44","author":"Grazette","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.09.007_bib9","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2006.05.057","article-title":"Neuregulin-1\/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy","volume":"48","author":"Liu","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jaccao.2022.09.007_bib10","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2005.01.014","article-title":"Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule","volume":"23","author":"Baselga","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.jaccao.2022.09.007_bib11","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1200\/JCO.20.00184","article-title":"Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients","volume":"38","author":"Sawaki","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.jaccao.2022.09.007_bib12","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaccao.2022.09.007_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR Database System: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"issue":"1","key":"10.1016\/j.jaccao.2022.09.007_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"21","key":"10.1016\/j.jaccao.2022.09.007_bib15","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1002\/sim.2473","article-title":"Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events","volume":"25","author":"Nor\u00e9n","year":"2006","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.jaccao.2022.09.007_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"15","key":"10.1016\/j.jaccao.2022.09.007_bib17","article-title":"Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction","volume":"7","author":"Nowsheen","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.jaccao.2022.09.007_bib18","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.jaccao.2022.09.007_bib19","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2022.09.007_bib20","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.jaccao.2022.09.007_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0079543","article-title":"Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice","volume":"8","author":"ElZarrad","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaccao.2022.09.007_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer","volume":"126","author":"Pond\u00e9","year":"2020","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.jaccao.2022.09.007_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.jaccao.2022.09.007_bib24","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jaccao.2022.09.007_bib25","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.09.007_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111682","article-title":"Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985)","volume":"183","author":"Xu","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.jaccao.2022.09.007_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"22","key":"10.1016\/j.jaccao.2022.09.007_bib28","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jaccao.2022.09.007_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.jaccao.2022.09.007_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.jaccao.2022.09.007_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.jaccao.2022.09.007_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-015-0006-7","article-title":"Cardiac safety of afatinib: a review of data from clinical trials","volume":"1","author":"Ewer","year":"2015","journal-title":"Cardio-Oncology"},{"issue":"8","key":"10.1016\/j.jaccao.2022.09.007_bib33","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00018-019-03340-w","article-title":"Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: insights from in\u00a0vitro, in\u00a0vivo, and clinical studies in breast cancer patients","volume":"77","author":"Leemasawat","year":"2020","journal-title":"Cell Mol Life Sci"},{"issue":"25","key":"10.1016\/j.jaccao.2022.09.007_bib34","doi-asserted-by":"crossref","first-page":"10607","DOI":"10.1073\/pnas.0701286104","article-title":"Activation of AMP-activated protein kinase by human EGF receptor 2\/EGF receptor tyrosine kinase inhibitor protects cardiac cells","volume":"104","author":"Spector","year":"2007","journal-title":"Proc Natl Acad Sci U\u00a0S A"},{"issue":"34","key":"10.1016\/j.jaccao.2022.09.007_bib35","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1200\/JCO.2009.22.1507","article-title":"Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer","volume":"27","author":"Spector","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.jaccao.2022.09.007_bib36","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","article-title":"Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a random","volume":"14","author":"Buzdar","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9712","key":"10.1016\/j.jaccao.2022.09.007_bib37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab vs neoadjuvant chemotherapy alone, in patients with HER2+ locally advanced breast cancer (NOAH trial): randomised controlled superiority trial with parallel HER2-negative cohort","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.jaccao.2022.09.007_bib38","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin \/cyclophosphamide followed by paclitaxel (ACP) with ACP\/trastuzumab as adjuvant therapy for patients with node-positive, HER2+ breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2022.09.007_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial","volume":"34","author":"Advani","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.jaccao.2022.09.007_bib40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jaccao.2022.09.007_bib41","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.21.01736","article-title":"Risk of cardiovascular disease in women with and without breast cancer: the Pathways Heart Study","volume":"40","author":"Greenlee","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaccao.2022.09.007_bib42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0891-5849(97)00025-7","article-title":"Analyses of the molecular mechanism of Adriamycin-induced cardiotoxicity","volume":"23","author":"Gille","year":"1997","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"10.1016\/j.jaccao.2022.09.007_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12012-007-0016-2","article-title":"Pathophysiology and diagnosis of cancer drug induced cardiomyopathy","volume":"7","author":"Zuppinger","year":"2007","journal-title":"Cardiovasc Toxicol"},{"issue":"9","key":"10.1016\/j.jaccao.2022.09.007_bib44","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/annonc\/mdn292","article-title":"Anthracycline-trastuzumab regimens for HER2\/neu-overexpressing breast cancer: current experience and future strategies","volume":"19","author":"Rayson","year":"2008","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.jaccao.2022.09.007_bib45","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","article-title":"Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1\u03b2 and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity","volume":"105","author":"Sawyer","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jaccao.2022.09.007_bib46","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.yjmcc.2006.08.002","article-title":"Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes","volume":"41","author":"Timolati","year":"2006","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.09.007_bib47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.yexcr.2005.08.017","article-title":"Neuregulin-1\u03b1 and \u03b2 isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in\u00a0vitro","volume":"311","author":"Cote","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jaccao.2022.09.007_bib49","unstructured":"U.S. Food and Drug Administration. Herceptin (trastuzumab). Accessed April 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5250lbl.pdf"},{"key":"10.1016\/j.jaccao.2022.09.007_bib50","unstructured":"U.S. Food and Drug Administration. Kadcyla (trastuzumab emtansine). Accessed April 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125427lbl.pdf"},{"key":"10.1016\/j.jaccao.2022.09.007_bib51","unstructured":"U.S. Food and Drug Administration. Perjeta (pertuzumab). Accessed April 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125409lbl.pdf"},{"key":"10.1016\/j.jaccao.2022.09.007_bib52","unstructured":"U.S. Food and Drug Administration. Lapatinib. Accessed April 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022059s007lbl.pdf"},{"key":"10.1016\/j.jaccao.2022.09.007_bib53","unstructured":"U.S. Food and Drug Administration. Enhertu (trastuzumab deruxtecan). Accessed April 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761139s011lbl.pdf"},{"issue":"11","key":"10.1016\/j.jaccao.2022.09.007_bib54","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jaccao.2022.09.007_bib55","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2011.37.4207","article-title":"Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Corte\u015b","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaccao.2022.09.007_bib56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2022.09.007_bib57","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(09)70087-7","article-title":"Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study","volume":"10","author":"Kaufman","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322005154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322005154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:56:05Z","timestamp":1762973765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322005154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2666087322005154"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.007","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacovigilance Analysis of Heart\u00a0Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}